Department of General Surgery, Guangdong Provincial People's Hospital Zhuhai Hospital (Zhuhai Golden Bay Center Hospital), Zhuhai, China.
Department of Thyroid Surgery, Cixi People's Hospital Medical and Health Group, Ningbo, China.
J Clin Lab Anal. 2022 Sep;36(9):e24609. doi: 10.1002/jcla.24609. Epub 2022 Jul 15.
CCT6A promotes several carcinomas' growth and invasion in multiple ways, and it relates to CCNB1 and PLK1 through its interaction with CDC20 via protein-protein interaction bioinformatics. This study aimed to explore the intercorrelation among CCT6A, CDC20, CCNB1, and PLK1, and their association with tumor features and prognosis in papillary thyroid carcinoma (PTC) patients.
CCT6A, CDC20, CCNB1, and PLK1 expressions in 186 tumor and 30 non-tumor specimens from PTC patients were determined by immunohistochemical (IHC). Clinical features, disease-free survival (DFS), and overall survival (OS) were retrieved.
CCT6A, CDC20, CCNB1, and PLK1 expressions were upregulated in tumor tissues compared with non-tumor tissues (all p < 0.001). CCT6A expression positively correlated with CDC20, CCNB1, and PLK1 expressions; besides, CDC20 expression positively associated with CCNB1 and PLK1 expressions, and CCNB1 expression was also positively related to PLK1 expression (all p < 0.05). Moreover, elevated tumor CCT6A expression was correlated with extrathyroidal invasion (p = 0.015), higher pT stage (p < 0.001), pN stage (p = 0.046), and pTNM stage (p = 0.042); while tumor CDC20, CCNB1, and PLK1 expressions only correlated with some of these indexes (most p < 0.05). Notably, CCT6A and CDC20 high expressions predicted worse DFS and OS (all p < 0.05); CCNB1 positive expression only predicted poor DFS (p = 0.044) but not OS (p = 0.152); however, PLK1 expression failed to predict these two indexes (both p > 0.05). After adjustment using multivariate Cox's regression, CCT6A expression (high vs. low) independently estimated shorter DFS (p = 0.010) and OS (p = 0.006).
CCT6A, CDC20, CCNB1, and PLK1 are intercorrelated, and they exhibit certain prognostic values in PTC patients.
CCT6A 通过与 CDC20 蛋白-蛋白相互作用，以多种方式促进多种癌症的生长和侵袭，并且与 CCNB1 和 PLK1 相关。本研究旨在探讨 CCT6A、CDC20、CCNB1 和 PLK1 之间的相互关系，以及它们与甲状腺乳头状癌（PTC）患者肿瘤特征和预后的关系。
采用免疫组织化学（IHC）方法检测 186 例 PTC 患者肿瘤组织和 30 例非肿瘤组织中 CCT6A、CDC20、CCNB1 和 PLK1 的表达情况。检索临床特征、无病生存（DFS）和总生存（OS）。
与非肿瘤组织相比，肿瘤组织中 CCT6A、CDC20、CCNB1 和 PLK1 的表达上调（均 p<0.001）。CCT6A 表达与 CDC20、CCNB1 和 PLK1 表达呈正相关；此外，CDC20 表达与 CCNB1 和 PLK1 表达呈正相关，CCNB1 表达也与 PLK1 表达呈正相关（均 p<0.05）。此外，肿瘤 CCT6A 高表达与甲状腺外侵犯相关（p=0.015），与较高的 pT 分期（p<0.001）、pN 分期（p=0.046）和 pTNM 分期（p=0.042）相关；而肿瘤 CDC20、CCNB1 和 PLK1 的表达仅与其中一些指标相关（多数 p<0.05）。值得注意的是，CCT6A 和 CDC20 高表达预测 DFS 和 OS 较差（均 p<0.05）；CCNB1 阳性表达仅预测 DFS 不良（p=0.044），但不预测 OS（p=0.152）；然而，PLK1 表达未能预测这两个指标（均 p>0.05）。经多因素 Cox 回归校正后，CCT6A 表达（高 vs. 低）独立预测 DFS 更短（p=0.010）和 OS 更短（p=0.006）。
CCT6A、CDC20、CCNB1 和 PLK1 相互关联，在 PTC 患者中具有一定的预后价值。
